{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:07:30Z","timestamp":1792152450640,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50171-4","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:37:51Z","timestamp":1777556271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-0454","authenticated-orcid":false,"given":"Arshdeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-7758","authenticated-orcid":false,"given":"Arshia","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-2696","authenticated-orcid":false,"given":"Riya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-503X","authenticated-orcid":false,"given":"Dharmatma","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2345-4948","authenticated-orcid":false,"given":"Devanshi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-4565","authenticated-orcid":false,"given":"Namita","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-6545","authenticated-orcid":false,"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-3969","authenticated-orcid":false,"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6389","authenticated-orcid":false,"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"3","key":"50171_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","volume":"9","author":"P Rivi\u00e8re","year":"2024","unstructured":"Rivi\u00e8re, P. et al. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol. Hepatol. 9 (3), 251\u2013262. https:\/\/doi.org\/10.1016\/S2468-1253(23)00313-8 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"50171_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","volume":"13","author":"P Hindryckx","year":"2016","unstructured":"Hindryckx, P., Jairath, V. & D\u2019Haens, G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat. Rev. Gastroenterol. Hepatol. 13 (11), 654\u2013664. https:\/\/doi.org\/10.1038\/nrgastro.2016.116 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"50171_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","volume":"4","author":"LC Dinesen","year":"2010","unstructured":"Dinesen, L. C. et al. The pattern and outcome of acute severe colitis. J. Crohns Colitis. 4 (4), 431\u2013437. https:\/\/doi.org\/10.1016\/j.crohns.2010.02.001 (2010).","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"50171_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis, S. P. et al. Predicting outcome in severe ulcerative colitis. Gut 38 (6), 905\u2013910. https:\/\/doi.org\/10.1136\/gut.38.6.905 (1996).","journal-title":"Gut"},{"issue":"4947","key":"50171_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 2 (4947), 1041\u20131048. https:\/\/doi.org\/10.1136\/bmj.2.4947.1041 (1955).","journal-title":"Br. Med. J."},{"issue":"2","key":"50171_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","volume":"16","author":"A Spinelli","year":"2022","unstructured":"Spinelli, A. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J. Crohns Colitis. 16 (2), 179\u2013189. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab177 (2022).","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"50171_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","volume":"61","author":"SPL Travis","year":"2012","unstructured":"Travis, S. P. L. et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61 (4), 535\u2013542. https:\/\/doi.org\/10.1136\/gutjnl-2011-300486 (2012).","journal-title":"Gut"},{"key":"50171_CR8","doi-asserted-by":"publisher","unstructured":"Honap, S. et al. Acute severe ulcerative colitis trials: the past, the present and the future. Gut. Published online June 4, 2024:gutjnl-2024-332489. https:\/\/doi.org\/10.1136\/gutjnl-2024-332489","DOI":"10.1136\/gutjnl-2024-332489"},{"issue":"1","key":"50171_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.dld.2003.04.001","volume":"36","author":"M Daperno","year":"2004","unstructured":"Daperno, M. et al. Outcome of a conservative approach in severe ulcerative colitis. Dig. Liver Dis. Off J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver. 36 (1), 21\u201328. https:\/\/doi.org\/10.1016\/j.dld.2003.04.001 (2004).","journal-title":"Dig. Liver Dis. Off J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"issue":"5","key":"50171_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/00365521.2020.1757143","volume":"55","author":"A R\u00f6nnblom","year":"2020","unstructured":"R\u00f6nnblom, A. & Karlbom, U. Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome. Scand. J. Gastroenterol. 55 (5), 555\u2013559. https:\/\/doi.org\/10.1080\/00365521.2020.1757143 (2020).","journal-title":"Scand. J. Gastroenterol."},{"key":"50171_CR11","doi-asserted-by":"publisher","first-page":"jjae094","DOI":"10.1093\/ecco-jcc\/jjae094","volume":"17","author":"SK Mundhra","year":"2024","unstructured":"Mundhra, S. K. et al. Intravenous albumin infusion does not augment the response rate to a combination of exclusive enteral nutrition and intravenous steroids in acute severe ulcerative colitis: a randomized controlled trial. J Crohns Colitis Published online June. 17, jjae094. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae094 (2024).","journal-title":"J Crohns Colitis Published online June"},{"issue":"5","key":"50171_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/apt.16249","volume":"53","author":"P Sahu","year":"2021","unstructured":"Sahu, P. et al. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 53 (5), 568\u2013576. https:\/\/doi.org\/10.1111\/apt.16249 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"50171_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4291\/wjgp.v6.i1.13","volume":"6","author":"M Cioffi","year":"2015","unstructured":"Cioffi, M., Rosa, A. D., Serao, R., Picone, I. & Vietri, M. T. Laboratory markers in ulcerative colitis: Current insights and future advances. World J. Gastrointest. Pathophysiol. 6 (1), 13\u201322. https:\/\/doi.org\/10.4291\/wjgp.v6.i1.13 (2015).","journal-title":"World J. Gastrointest. Pathophysiol"},{"issue":"Pt 5","key":"50171_CR14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1469-1809.2007.00352.x","volume":"71","author":"DR Velez","year":"2007","unstructured":"Velez, D. R. et al. Ethnic differences in interleukin 6 (IL-6) and IL6 receptor genes in spontaneous preterm birth and effects on amniotic fluid protein levels. Ann. Hum. Genet. 71 (Pt 5), 586\u2013600. https:\/\/doi.org\/10.1111\/j.1469-1809.2007.00352.x (2007).","journal-title":"Ann. Hum. Genet."},{"issue":"2","key":"50171_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2478\/bjmg-2013-0032","volume":"16","author":"GG Gan","year":"2013","unstructured":"Gan, G. G., Subramaniam, R., Lian, L. H. & Nadarajan, V. Ethnic Variation in Interleukin-6 \u2013\u2009174 (G\/C) Polymorphism in the Malaysian Population. Balk. J. Med. Genet. BJMG. 16 (2), 53\u201358. https:\/\/doi.org\/10.2478\/bjmg-2013-0032 (2013).","journal-title":"Balk. J. Med. Genet. BJMG"},{"issue":"7","key":"50171_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/ecco-jcc\/jjac014","volume":"16","author":"A Croft","year":"2022","unstructured":"Croft, A., Lord, A. & Radford-Smith, G. Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis? J. Crohns Colitis. 16 (7), 1089\u20131096. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac014 (2022).","journal-title":"J. Crohns Colitis"},{"key":"50171_CR17","doi-asserted-by":"publisher","unstructured":"Singh, A. et al. Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial. Am J. Gastroenterol Published online January. 22 https:\/\/doi.org\/10.14309\/ajg.0000000000002635 (2024).","DOI":"10.14309\/ajg.0000000000002635"},{"issue":"1","key":"50171_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.15592","volume":"51","author":"C Dong","year":"2020","unstructured":"Dong, C., Metzger, M., Holsb\u00f8, E., Perduca, V. & Carbonnel, F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 51 (1), 8\u201333. https:\/\/doi.org\/10.1111\/apt.15592 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50171_CR19","doi-asserted-by":"publisher","unstructured":"Fernandes, R. G. et al. Acute Severe Ulcerative Colitis Patients From Asia Have Lower Colectomy Risk Than Patients From Australasia. Clin Gastroenterol. Hepatol. Off Clin. Pract. J. Am. Gastroenterol. Assoc Published online October 30, 2025:S1542-3565(25)00927-9. https:\/\/doi.org\/10.1016\/j.cgh.2025.10.019","DOI":"10.1016\/j.cgh.2025.10.019"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50171-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:35:00Z","timestamp":1782945300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50171-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50171"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50171-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shaji Sebastian has received consulting fees from Celltrion, BMS Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, Lilly and Tillots Pharma; has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, Falk Pharma, Janssen and Lilly. Laurent Peyrin-Biroulet consults for Abbvie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, BMS, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, Par\u2019 Immune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx, Ysopia and has received payment or honoraria for lectures from Abbvie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots, Viatris. Ajit Sood received honorarium for speaker events from Pfizer India and Takeda India. The remaining authors disclose no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by institutional ethics committee (DMCH\/R&D\/2020\/23).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"20172"}}